Applied Therapeutics Acquired by Cycle Group Holdings; Shares to Delist from Nasdaq

summarizeSummary

Applied Therapeutics, Inc. has been acquired by Cycle Group Holdings Limited, with the merger completed on February 3, 2026. As a result, the company's shares will be delisted from Nasdaq.

check_boxKey Events · M&A and Partnerships · APLT

• Merger Completed

  Cycle Group Holdings Limited completed the acquisition of Applied Therapeutics, Inc. on February 3, 2026, following the expiration of the tender offer.

• Tender Offer Results

  A total of 79,518,606 shares, representing approximately 51.56% of outstanding shares, were validly tendered and accepted, satisfying the minimum tender condition.

• Delisting from Nasdaq

  Applied Therapeutics shares ceased trading prior to the opening on February 3, 2026, and will be delisted from The Nasdaq Global Select Market.

• Consideration for Shareholders

  Shareholders will receive $0.088 per share in cash plus one non-tradeable contingent value right (CVR), which represents the contractual right to receive up to four contingent cash payments up to an aggregate of $0.40 per CVR, plus a pro rata portion of any closing cash payment.

auto_awesomeAnalysis · APLT · Life Sciences

This filing confirms the completion of the acquisition of Applied Therapeutics, Inc. by Cycle Group Holdings Limited, marking the end of Applied Therapeutics as a publicly traded entity. Shareholders will receive $0.088 per share in cash along with contingent value rights (CVRs) that offer potential future payments tied to the achievement of specific milestones for the company's lead drug candidate, govorestat. The delisting from Nasdaq means that APLT shares will no longer be traded on the open market, fundamentally altering the investment thesis for current shareholders. This follows several extensions of the tender offer, indicating a prolonged process to finalize the transaction.